Abstract
The interleukin-6 (IL-6) stimulates growth in cells such as multiple myeloma and B-cell plasmacytomas/hybridomas, while it inhibits growth in several myeloid leukemia cells. The IL-6 receptor has subunit called gp130. It was reported that Ser-782 of gp130 is phosphorylated by unidentified kinase(s) in cell extracts, and level of gp130 (S782A) transiently expressed on the cell surface of COS-7 is 6-times higher than that of the wild type. These results motivated us to analyze whether the phosphorylation of gp130 at Ser-782 is involved in its degradation or not. In this study, we demonstrated here that treatment of HepG2 cells with okadaic acid (OA), a potent inhibitor for PP2A, promotes phosphorylation of gp130 at Ser-782 and degradation of gp130. MG115, a proteasome inhibitor, suppressed this degradation. These effects of OA could not be replaced with tautomycetin (TC), an inhibitor for PP1. Purified PP2A dephosphorylated phospho-Ser-782 of gp130 in vitro. IL-6-induced activation of Stat3 was suppressed by preincubation of the cells with OA, suggesting that the IL-6 signaling pathway was blocked by OA through degradation of gp130. Taken together, present results strongly suggest that degradation of gp130 is regulated through a phosphorylation-dephosphorylation mechanism in which PP2A is crucially involved and that gp130 is a potential therapeutic target in cancers. (Mol Cell Biochem 269: 183–187, 2005)
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hirano T, Nakajima K, Hibi M: Signaling mechanisms through gp130: A model of the cytokine system. Cytokine & Growth Factor Reviews 8: 241–252, 1997
Ohtani T, Ishihara K, Atsumi T, Yoshida Y, Nishida K, Narimatsu M, Shirogane T, Hibi M, Hirano T: gp130-mediated signaling as a therapeutic target. Emerg Ther Target 4: 459–479, 2000
Chow DC, Brevnova L, He XL, Martick MM, Bankovich A, Garcia KC: A structural template for gp130-cytokine signaling assemblies. Biochim Biophys Acta. 1592: 225–235, 2002
Naka T, Nishimoto N, Kishimoto T: The paradigm of IL-6: From basic science to medicine. Arthritis Res. Suppl 3: S233–S242, 2002
Ernst M, Jenkins BJ: Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 20: 23–32, 2004
Tanuma N, Shima H, Nakamura K, Kikuchi K: Protein tyrosine phosphatase epsilonC selectively inhibits interleukin-6- and interleukin-10-induced JAK-STAT signaling. Blood 98: 3030–3034, 2001
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin IL -6-type cytokine signalling and its regulation. Biochem J 374: 1–20, 2003
Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, Legouffe E, De Vos J, Rossi JF: Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 78: 106–113, 2003
Trikha M, Corringham R, Klein B, Rossi JF: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 9: 4653–4665, 2003
Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM: Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago, Phase II consortium study. J Clin Oncol 22: 115–119, 2004
Tariman JD, Lemoine C: Bortezomib. Clin J Oncol Nurs 7: 687–689, 2003
Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC: Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22: 8386–8393, 2003
Gibson RM, Schiemann WP, Prichard LB, Reno JM, Ericsson LH, Nathanson NM: Phosphorylation of human gp130 at Ser-782 adjacent to the Di-leucine internalization motif. Effects on expression and signaling. J Biol Chem 275: 22574–22582, 2000
Mitsuhashi S, Shima H, Tanuma N, Matsuura N, Takekawa M, Urano T, Kataoka T, Ubukata M, Kikuchi K: Usage of tautomycetin, a novel inhibitor of protein phosphatase 1 PP1, reveals that PP1 is a positive regulator of Raf-1 in vivoJ Biol Chem 278: 82–88, 2003
Cheng XC, Ubukata M, Isono K: The structure of tautomycetin, a dialkylmaleic anhydride antibiotic. J Antibiot Tokyo 43: 890–896, 1990
Mitsuhashi S, Shima H, Kawamura T, Kikuchi K, Oikawa M, Ichihara A, Oikawa H: The spiroketals containing a benzyloxymethyl moiety at C8 position showed the most potent apoptosis-inducing activity. Bioorg Med Chem Lett 9: 2007–2012, 1999
Mitsuhashi S, Saito N, Watano K, Igarashi K, Tagami S, Shima H, Kikuchi K: Defect of delta-sarcoglycan gene is responsible for development of dilated cardiomyopathy of a novel hamster strain, J2N-k: Calcineurin/PP2B activity in the heart of J2N-k hamster. J Biochem Tokyo 134: 269–276, 2003
Kim SE, Ishita A, Shima H, Nakamura K, Yamada Y, Ogawa K, Kikuchi K: Increased expression of NIPP-1 mRNA correlates positively with malignant phenotype in rat hepatomas. Int J Oncol 16: 751–755, 2000
Kloeker S, Reed R, McConnell JL, Chang D, Tran K, Westphal RS, Law BK, Colbran RJ, Kamoun M, Campbell KS, Wadzinski BE: Parallel purification of three catalytic subunits of the protein serine/threonine phosphatase 2A family PP2A C, PP4 C, and PP6 C and analysis of the interaction of PP2A C with alpha4 protein. Protein Expr Purif 31: 19–33, 2003
Fukuda H, Shima H, Vesonder RF, Tokuda H, Nishino H, Katoh S, Tamura S, Sugimura T, Nagao M: Inhibition of protein serine/threonine phosphatases by fumonisin B1, a mycotoxin. Biochem Biophys Res Commun 220: 160–165, 1996
Schonthal AH: Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett 170: 1–13, 2001
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mitsuhashi, S., Shima, H., Tanuma, N. et al. Protein phosphatase type 2A, PP2A, is involved in degradation of gp130. Mol Cell Biochem 269, 183–187 (2005). https://doi.org/10.1007/s11010-005-3089-x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11010-005-3089-x